Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000244283 | SCV000309830 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV002313982 | SCV000848842 | likely benign | Inborn genetic diseases | 2016-04-15 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Labcorp Genetics |
RCV001087894 | SCV001109247 | benign | Neuronal ceroid lipofuscinosis 13 | 2024-01-19 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000675401 | SCV001143654 | benign | not provided | 2018-12-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000675401 | SCV001859206 | benign | not provided | 2019-08-30 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV001087894 | SCV002808260 | likely benign | Neuronal ceroid lipofuscinosis 13 | 2022-01-15 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001087894 | SCV004564093 | benign | Neuronal ceroid lipofuscinosis 13 | 2023-09-18 | criteria provided, single submitter | clinical testing | |
Breakthrough Genomics, |
RCV000675401 | SCV005216545 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Mayo Clinic Laboratories, |
RCV000675401 | SCV000801074 | benign | not provided | 2018-02-08 | no assertion criteria provided | clinical testing |